RE:This PP will be telling...reconsider wrote: if smart money sees what everybody here seems to see.
If by the end of next week we have $5M in, that would be a good sign. If on the contrary we struggle to get financing... that would mean that smart money doesn't buy Theralase's forward looking statements. And that is with a projected Q4 '23-Q1 '24 BTD (as stated in page 17 in the LIFE financing presentation)
Looking forward to seeing how this PP closes,
Reconsider, 9 years invested in TLTFF
Yes, a fully subscribed offering would certainly be the best outcome for the company's coffers and in terms of investor buy-in but I don't think it's necessarily a linear argument about "smart money". From what I've read about these LIFE financing arrangements, they have a no pre-marketing clause, so the timeline for soliciting investor participation is much more limited, pressuring the sales agent. Also, we must consider that broad market conditions have been terrible this year for issuances, especially in the small and micro cap sectors. The CR data to date would certainly argue that a fully subscribed offering should be a no brainer as the path toward commercialization should get much more clear next year but let's see if they can successfully get this closed next week.